Literature DB >> 6721991

Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.

M Eichelbaum, G Mikus, B Vogelgesang.   

Abstract

The pharmacokinetics of (+)-, (-)-, and (+/-)-verapamil were studied in five healthy volunteers following i.v. administration of the drugs. Pronounced differences of the various pharmacokinetic parameters were observed between the (-)- and (+)-isomers. The values for CL, V, Vz, and Vss of the (-)-isomer were substantially higher as compared to the (+)-isomer, whereas terminal t 1/ 2Z was nearly identical for both isomers. No dose dependency of the pharmacokinetics could be observed in two subjects who received 5, 7.5 and 10 mg of (-)- and 5, 25 and 50 mg of (+)-verapamil. Protein binding for the two isomers was also different. The fu of (-)- (0.11) was almost twice as much as that of (+)-verapamil (0.064). Pharmacokinetic parameters of (+/-)-verapamil, which was administered to three subjects who had received (+)- and (-)-verapamil, were very similar to the averaged values of the isomers given separately. Due to the higher CL of (-)-verapamil the extraction ratio of the (-)-isomer is substantially higher. Thus, it can be anticipated that following oral administration of racemic verapamil bioavailability of (-)-verapamil will be substantially less. Since the (-)-isomer is more potent than the (+)-isomer, the present findings could explain the reported differences in the concentration-effect relationship after i.v. and oral administration of racemic verapamil.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721991      PMCID: PMC1463390          DOI: 10.1111/j.1365-2125.1984.tb02371.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard.

Authors:  B Spiegelhalder; M Eichelbaum
Journal:  Arzneimittelforschung       Date:  1977

2.  Nonlinear least-squares regression programs for microcomputers.

Authors:  C C Peck; B B Barrett
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

3.  Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response.

Authors:  M Eichelbaum; M Albrecht; G Kliems; K Schäfer; A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

4.  Comparison of intravenous and oral verapamil dosing.

Authors:  M J Reiter; D G Shand; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1982-12       Impact factor: 6.875

5.  Relationship of antiarrhythmic to inotropic activity and antiarrhythmic qualities of the optical isomers of verapamil.

Authors:  M Raschack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-09       Impact factor: 3.000

6.  Effects of verapamil and its optical isomers on repetitive slow responses induced by electrical depolarization in canine ventricular myocardium.

Authors:  T Saikawa; M Arita
Journal:  Jpn Heart J       Date:  1980-03

7.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

8.  Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships.

Authors:  B G Woodcock; I Rietbrock; H F Vöhringer; N Rietbrock
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

9.  Effects on atrioventricular conduction and blood flow of enantiomers of verapamil and of tetrodotoxin injected into the posterior and the anterior septal artery of the atrioventricular node preparation of the dog.

Authors:  K Satoh; T Yanagisawa; N Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

10.  Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets.

Authors:  M Eichelbaum; H J Dengler; A Somogyi; G E von Unruh
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

View more
  47 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

Authors:  D N John; S Fort; M J Lewis; D K Luscombe
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 3.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 5.  New concepts affecting the use of antiarrhythmic agents.

Authors:  R L Woosley
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 6.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

7.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 8.  Stereoselectivity in pharmacokinetics: a general theory.

Authors:  R H Levy; A V Boddy
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

Review 9.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

10.  Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding.

Authors:  K Hanada; S Akimoto; K Mitsui; K Mihara; H Ogata
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.